NYSE:ZYME - Zymeworks Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.56 -0.50 (-2.93 %)
(As of 06/21/2018 06:10 AM ET)
Previous Close$17.06
Today's Range$16.35 - $17.45
52-Week Range$6.25 - $29.00
Volume167,571 shs
Average Volume379,346 shs
Market Capitalization$542.81 million
P/E Ratio-29.05
Dividend YieldN/A
Beta5.53
Zymeworks logoZymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Debt-to-Equity RatioN/A
Current Ratio4.09
Quick Ratio4.09

Price-To-Earnings

Trailing P/E Ratio-29.05
Forward P/E Ratio-6.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$51.76 million
Price / Sales10.18
Cash FlowN/A
Price / CashN/A
Book Value$4.59 per share
Price / Book3.61

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-10,400,000.00
Net Margins-30.41%
Return on Equity-16.07%
Return on Assets-13.65%

Miscellaneous

Employees147
Outstanding Shares31,820,000

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings data on Tuesday, May, 1st. The company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.15. The company had revenue of $0.04 million for the quarter. Zymeworks had a negative return on equity of 16.07% and a negative net margin of 30.41%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

7 equities research analysts have issued 12-month price targets for Zymeworks' shares. Their forecasts range from $15.00 to $37.00. On average, they expect Zymeworks' share price to reach $25.00 in the next year. View Analyst Ratings for Zymeworks.

Who are some of Zymeworks' key competitors?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 46)
  • Mr. Neil Klompas C.A., C.P.A., CPA, CA, Chief Financial Officer (Age 46)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 55)
  • Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)
  • Mr. David Tucker, Chief Operating Officer

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Has Zymeworks been receiving favorable news coverage?

News articles about ZYME stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zymeworks earned a coverage optimism score of 0.18 on Accern's scale. They also gave press coverage about the company an impact score of 46.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of of retail and institutional investors. Top institutional investors include PenderFund Capital Management Ltd. (1.28%) and Stanley Laman Group Ltd. (0.14%). View Institutional Ownership Trends for Zymeworks.

Which major investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including PenderFund Capital Management Ltd. and Stanley Laman Group Ltd.. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $16.56.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $542.81 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.